ERBB2 (HER2) protein expression in uterine sarcomas

被引：0
作者：
Zafrakas, M. [1 ]
Zepiridis, L. [1 ]
Theodoridis, T. D. [1 ]
Venizelos, I. D. [2 ]
Papanicolaou, A. [1 ]
Agorastos, T. [1 ]
Bontis, J. N. [1 ]
机构：
[1] Aristotle Univ Thessaloniki, Dept Obstet & Gynecol 1, Papageorgiou Gen Hosp, Thessaloniki 56403, Greece
[2] Hippokrateio Gen Hosp, Dept Pathol, Thessaloniki, Greece
来源：
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY | 2009年 / 30卷 / 03期
关键词：
Uterine sarcoma; ERBB2; HER2; Targeted therapy; Trastuzumab; Herceptin (R); Lapatinib; Tykerb (R); METASTATIC BREAST-CANCER; RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; OF-THE-LITERATURE; ADJUVANT CHEMOTHERAPY; GENE AMPLIFICATION; TRASTUZUMAB; CARCINOSARCOMA; HER-2/NEU; THERAPY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose: Multiple clinical trials in recent years have shown that breast cancer patients with primary tumors overexpressing ERBB2 can be effectively treated with specific forms of modern anti-ERBB2-targeted therapy. The aim of the present study was to analyze the expression of the ERBB2 (HER2) protein in uterine sarcomas, in order to investigate the possibility of applying this treatment modality in uterine sarcomas. Methods: The expression of ERBB2 has been analyzed immunohistochemical in formalin-fixed paraffin-embedded primary uterine sarcomas (n = 11). Results: Using a semi-quantitative immunohistochemical score, we found that ERBB2 expression was very weak in the majority of tumors, with only three sarcomas showing moderate ERBB2 expression. Published studies evaluating the same issue in small numbers of uterine sarcomas reached similar findings. Conclusion: Overall, ERBB2 expression appears to be weak in uterine sarcomas. However, targeted treatment might still be feasible in a subgroup of patients with uterine sarcomas overexpressing ERBB2.
引用
收藏
页码：292 / 294
页数：3
相关论文
共 50 条
  • [31] Challenges in the treatment of ErbB2 (HER2)-positiive breast cancer
    Jackisch, Christian
    EJC SUPPLEMENTS, 2008, 6 (05): : 7 - 14
  • [32] Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
    Wang, Xin-Yu
    Zheng, Zhi-Xue
    Sun, Yu
    Bai, Yan-Hua
    Shi, Yun-Fei
    Zhou, Li-Xin
    Yao, Yun-Feng
    Wu, Ai-Wen
    Cao, Deng-Feng
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 11 (04) : 335 - 347
  • [33] Dual HER2 Targeting Impedes Growth of HER2 Gene-Amplified Uterine Serous Carcinoma Xenografts
    Groeneweg, Jolijn W.
    Hernandez, Silvia F.
    Byron, Virginia F.
    DiGloria, Celeste M.
    Lopez, Hector
    Scialabba, Vanessa
    Kim, Minji
    Zhang, Ling
    Borger, Darrell R.
    Tambouret, Rosemary
    Foster, Rosemary
    Rueda, Bo R.
    Growdon, Whitfield B.
    CLINICAL CANCER RESEARCH, 2014, 20 (24) : 6517 - 6528
  • [34] Clinicopathological value of ErbB2 gene and protein expression in osteochondroma
    Huang, Zhen
    Wang, Sheng-Lin
    Huang, Qing-Shan
    Li, Xiao-Dong
    Chen, Hui
    Lin, Jian-Hua
    ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA, 2020, 54 (01) : 34 - 41
  • [35] The human epidermal growth factor receptor 2 (HER2)
    Tafe, Laura J.
    Tsongalis, Gregory J.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2012, 50 (01) : 23 - 30
  • [36] Detection of ERBB2 and CEN17 signals in fluorescent in situ hybridization and dual in situ hybridization for guiding breast cancer HER2 target therapy
    Wang, Ching-Wei
    Khalil, Muhammad-Adil
    Lin, Yi-Jia
    Lee, Yu-Ching
    Chao, Tai-Kuang
    ARTIFICIAL INTELLIGENCE IN MEDICINE, 2023, 141
  • [37] Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
    Schroeder, Richard L.
    Stevens, Cheryl L.
    Sridhar, Jayalakshmi
    MOLECULES, 2014, 19 (09) : 15196 - 15212
  • [38] Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin
    Chmielecki, Juliann
    Ross, Jeffrey S.
    Wang, Kai
    Frampton, Garrett M.
    Palmer, Gary A.
    Ali, Siraj M.
    Palma, Norma
    Morosini, Deborah
    Miller, Vincent A.
    Yelensky, Roman
    Lipson, Doron
    Stephens, Philip J.
    ONCOLOGIST, 2015, 20 (01) : 7 - 12
  • [39] Amplification and expression of EGFR and ERBB2 in Wilms tumor
    Vasei, Mohammad
    Modjtahedi, Helmout
    Ale-booyeh, Oreineb
    Mosallaei, Ahmad
    Kajbafzadeh, Abdol Mohammad
    Shahriari, Mehdi
    Ghaderi, Abbas Ali
    Soleymanpour, Hossein
    Kosari, Farid
    Moch, Holger
    Sauter, Guido
    CANCER GENETICS AND CYTOGENETICS, 2009, 194 (02) : 88 - 95
  • [40] Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance
    Sellappan, Shankar
    Blackler, Adele
    Liao, Wei-Li
    O'Day, Emily
    Xu, Peng
    Thyparambil, Sheeno
    Cecchi, Fabiola
    Hembrough, Todd
    Catenacci, Daniel V. T.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (05): : 503 - 507
12345